News Insilico ends 2025 with $293m Hong Kong IPO One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
News Ultragenyx, Mereo's brittle bone drug flames out in trials Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.
News Judge blocks HHS' 340B rebate pilot at 11th hour A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
News J&J abandons trial of atopic dermatitis drug J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.
News No Christmas present for Sanofi, as FDA turns down MS drug FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026.
News Biosimilars unlock use of bevacizumab in bowel cancer by NHS More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
